Dexcom G7

the most accurate CGM. Period.[1-3]

DEXCOM CGM FEATURES DEMONSTRATE PROVEN OUTCOMES IN A1C REDUCTION, TIR,[4-8] AND IMPROVED DEVICE ADHERENCE[9]

Significantly **increased TIR** and demonstrated a **>1% A1C reduction** after 12 weeks[4-6]

CGM and GLP-1 agonist helped people with uncontrolled T2D achieve a **1.83% A1C reduction**[1,*]

Urgent Low Soon alert to reduce rebound **hyperglycemia**[10,11,†] and Delay 1st high alert to reduce rebound **hypoglycemia**[12]

Smart devices sold separately.
For a list of compatible devices, visit dexcom.com/compatibility.

To learn more, visit: provider.dexcom.com/pharmacists

CGM = continuous glucose monitoring; GLP-1 = glucagon-like peptide 1; T2D = type 2 diabetes; TIR = time in range.

*The data comes from a 2018-2023 US database of payor claims as a retrospective, observational analysis. Dexcom CGM + GLP-1 (N = 101) vs. GLP-1 only (N = 5840). The GLP-1 only group (control) showed a 0.99% A1C reduction. †Predictive alert at 55 mg/dL within 20 minutes.

BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

1 Dexcom, data on file, 2023. 2 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K213919. Published December 7, 2022. Accessed March 12, 2024. https://www.accessdata.fda.gov/cdrh_docs/reviews/K213919.pdf 3 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K222447. Published March 3, 2023. Accessed March 12, 2024. https://www.accessdata.fda.gov/cdrh_docs/reviews/K222447.pdf 4 Beck RW, et al. *JAMA*. 2017;317(4):371-378. 5 Beck RW, et al. *Ann Intern Med*. 2017;167(6):365-374. 6 Welsh JB, et al. *J Diabetes Sci Technol*. 2024;18(1):143-147. 7 Martens T, et al. *JAMA*. 2021;325(22):2262-2272. 8 Laffel LM, et al. *JAMA*. 2020;323(23):2388-2396. 9 Nemlekar P, et al. *Diabetes Ther*. 2024;15(3):639-648. 10 Dexcom G7 CGM System User Guide, 2023. 11 Acciaroli G, et al. *J Diabetes Sci Technol*. 2022;16(3):677-682. 12 Wilmot E. Dexcom G7: Unique Features and Correlational Improvements in Glycemic Control. Presented at the 16th International ATTD Conference on February 23, 2023.

Dexcom